Physician profile
Tim Anderson
NPI 1598291775
$357.89
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.09 · 2021: $83.10 · 2022: $185 · 2023: $64.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $64.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $64.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $64.23 | 2022-2023 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.02 | 2022 | |
| Janssen Pharmaceuticals, INC | $42.38 | 2022 | |
| Alexion Pharmaceuticals, INC. | $36.57 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.92 | 2022-2023 | |
| United Therapeutics Corporation | $21.95 | 2022 | |
| Astellas Pharma US INC | $21.02 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.04 | 2023 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $15.23 | 2022 | |
| Sanofi Pasteur INC. | $14.17 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.12 | 2021 | |
| Pulmonx Corporation | $12.93 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Sandoz INC. | $12.39 | 2021 | |
| Covidien LP | $11.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tim Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.